Brief: Medicenna Shows Promising Pre-Clinical Results In Solid Tumor Models With Its Il-2 Superkine, Mdna109
06/02/2019 12:38
Feb 6 (Reuters) - Medicenna Therapeutics Corp MDNA.TO :
* MEDICENNA SHOWS PROMISING PRE-CLINICAL RESULTS IN SOLID
TUMOR
MODELS WITH ITS IL-2 SUPERKINE, MDNA109
* MEDICENNA THERAPEUTICS CORP - MAGNIFIED IL-2 AFFINITY
TOWARDS
CD122 POTENTLY SYNERGIZES WITH CHECKPOINT INHIBITORS
Source text for Eikon: ID:nCNWtGlZqa
Further company coverage: MDNA.TO
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Medicenna Therapeutics
See all newsBrief: Medicenna Therapeutics - Announces Two New U.S. Patents And One Allowed U.S. Patent Application
Brief: Medicenna Announces The Finalization Of The Terms Of Its Public Offering Of Securities
Brief: Medicenna Announces The Launch Of A Marketed Public Offering Of Securities
Brief: Medicenna Therapeutics Appoints Dr. Nageatte Ibrahim As Chief Medical Officer
Brief: Medicenna Therapeutics Reports Third Quarter Fiscal 2026 Financial Results